Consumers are quietly rewriting the rules of beauty and wellness. As more “science‑backed” and “longevity‑backed” products launch, often with slower, compounding results rather than instant fixes, people are asking harder questions.
They don’t just want elegant stories or aspirational imagery anymore; they want evidence that their time, money and long‑term commitment are actually paying off.
You can hear it in the questions they ask: Is my skin really changing? Is my biological age shifting? Is this protocol doing anything beyond the placebo effect?
That growing pressure is forcing brands and clinics to confront a fundamental issue at the heart of this new landscape: who should own testing and diagnostics in beauty and longevity, and what does “proof” really look like?
Diagnostics are quickly becoming the bridge between what brands sell and what consumers can measure. For years, brands have sold ingredients, formulations, promises and carefully staged before‑and‑after images.
Now, the next generation may be expected to deliver something quite different: measurable improvement, personalised recommendations, ongoing progress tracking and experiences built around outcomes rather than claims.
That shift raises uncomfortable but important questions. Should every longevity or wellness brand offer testing as part of its proposition? Or is it wiser for brands to partner with established diagnostics players and focus on what they do best? Which biomarkers actually make sense to bring to a consumer audience, and which ones create more confusion than clarity? And if a customer starts to collect their own health and skin data, how does that change the way they choose and stay with products over time?
For a skincare line, supplement company or wellness brand, diagnostics can sit in very different places in the strategy. It might be a marketing layer that offers proof and differentiation, a customer‑engagement engine that keeps people coming back to see their progress, a scientific validation tool that underpins claims, or even the foundation of a completely new business model built around data and outcomes rather than units sold.
A key strategic task now is deciding which of these roles, if any, genuinely serves the brand and its customers, rather than simply adding complexity because “everyone else is doing it.”
Clinics are already much further along this curve. Many aesthetic and longevity clinics routinely work with biological age tests, blood biomarkers, hormone panels, skin analysis, microbiome profiles and genetic tests. For them, the question is no longer “Can we test?” but “Which tests actually create value?” Which diagnostics truly improve outcomes, adherence and long‑term engagement and which ones generate impressive reports that don’t meaningfully change care?
Read more: From Products to Protocols: The Next Evolution of Consumer Health
Clinics also hold something brands are increasingly hungry for: direct insight into what real people are asking for, what they are confused by, and what they are willing to pay for when it comes to diagnostics. That perspective is essential for anyone designing the next generation of beauty, wellness and longevity products and programs.
This is where the conversation between brands and clinics becomes most interesting. Right now, many brands have products, and many clinics have data. The future likely belongs to those who can intelligently combine both.
Imagine a supplement brand that doesn’t just promise “support for healthy ageing” but tracks biological age over years; a skincare brand that builds routine design around objective skin‑health assessments; a longevity clinic that recommends specific products and protocols based on a coherent diagnostic framework rather than a shelf of unconnected SKUs.
Making that future real, however, means resolving some tough questions. What makes a diagnostic test trustworthy in the eyes of clinicians, regulators, and consumers? How should brands think about building versus buying versus partnering when it comes to testing capabilities? Where is the line between meaningful personalisation and gimmickry? And how do we avoid a world where diagnostics become yet another marketing veneer, rather than a tool that genuinely improves outcomes?
These are exactly the questions we’ll be exploring at INNOCOS Zurich in our panel “Diagnostics & Biological Age: What should brands own in testing?”, where diagnostics sits at the intersection of beauty, wellness, longevity, clinics and consumer products. But they’re not just conference questions, they’re strategic questions for anyone who wants to build credible, future‑proof offerings in this space.
